Breast Cancer Risk Cut
in Half with Evista - STAR Study Indicates Protection Offered By
Raloxifene HCL - No Reduction in Heart Death
April 18th 2006
Researchers have determined that Evista (raloxifene HCL) can reduce the
risk of developing breast cancer by about half. The Study of Tamoxifen
and Raloxifene (STAR) found that Evista, an osteoporosis drug, works as
well as the older drug used to treat cancer, tamoxifen, in reducing the
risk of breast cancer in high-risk women, but with fewer dangerous side
Evista is marketed by Eli Lilly for the treatment of osteoporosis in
postmenopausal women. The new breast cancer protection findings were
announced by the National Surgical Adjuvant Breast and Bowel Project (NSABP).
Steven Paul, M.D., executive vice president of science and technology,
Lilly said “NSABP's STAR study represents an important milestone in
Eli Lilly and company, the maker of the drug, announced they will likely
petition the Food and Drug Administration (FDA) to allow the drug to be
prescribed for patients at high risk of developing breast cancer.
Currently, raloxifene is not approved by the FDA for preventing or
reducing the risk of cardiovascular disease or invasive breast cancer.